Opioid-Withdrawal 'Aids' Warrant Immediate FDA, FTC Action – CSPI
This article was originally published in The Rose Sheet
FDA and the Federal Trade Commission should bring immediate enforcement action against marketers of non-kratom dietary supplements promoted as opioid-withdrawal aids, says the Center for Science in the Public Interest in letters to the agency and commission Dec. 8. The nonprofit identified eight supplement products making opioid-withdrawal claims without sufficient science to support the statements.
You may also be interested in...
As in previous warnings to kratom supplement marketers linked to opioid addiction treatment claims, FDA tells Cali Botanicals and Kratom NC that HHS in 2017 found opioid abuse was nationwide public health emergency and FDA is targeting products that without approval claim to diagnose, mitigate, prevent, treat or cure opioid addiction. Contract manufacturer Somlabs' GMP problems also were identified in FDA's latest warning letters.
The Center for Science in the Public Interest urges the US Food and Drug Administration to seize products from marketers of 15 dietary supplements that claim to treat nicotine addiction. In an April 24 letter, the advocacy group says none of the marketers could present evidence in support of claims promising quick relief from addiction and/or results comparable to FDA-approved Rx and OTC drug products.
PoppySeed Wash ‘medicinal’ beverage claiming to help ease opioid withdrawal and ease pain is an unapproved new drug and is misbranded, FDA says. Agency's warning is latest on supplements making opioid withdrawal claims, but the action has not prompted the Utah firm to discontinue selling its product online.